Compare ZURA & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZURA | LNSR |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 142.0M |
| IPO Year | N/A | N/A |
| Metric | ZURA | LNSR |
|---|---|---|
| Price | $3.51 | $10.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | $11.38 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 408.9K | 75.6K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,141,000.00 |
| Revenue This Year | N/A | $30.80 |
| Revenue Next Year | N/A | $33.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $0.97 | $7.13 |
| 52 Week High | $4.68 | $17.31 |
| Indicator | ZURA | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 43.36 |
| Support Level | $3.57 | $9.56 |
| Resistance Level | $3.95 | $10.48 |
| Average True Range (ATR) | 0.27 | 0.37 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 0.43 | 74.31 |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.